Jove
Visualize
Contact Us
JoVE
x logofacebook logolinkedin logoyoutube logo
ABOUT JoVE
OverviewLeadershipBlogJoVE Help Center
AUTHORS
Publishing ProcessEditorial BoardScope & PoliciesPeer ReviewFAQSubmit
LIBRARIANS
TestimonialsSubscriptionsAccessResourcesLibrary Advisory BoardFAQ
RESEARCH
JoVE JournalMethods CollectionsJoVE Encyclopedia of ExperimentsArchive
EDUCATION
JoVE CoreJoVE BusinessJoVE Science EducationJoVE Lab ManualFaculty Resource CenterFaculty Site
Terms & Conditions of Use
Privacy Policy
Policies

Filters

S M Hwang

Showing results (111-120 of 122) with videos related to

Pageof 13
Sort By:
Bone|September 12, 2006
A highly potent inhibitor of cathepsin K (relacatib) reduces biomarkers of bone resorption both in vitro and in an acute model of elevated bone turnover in vivo in monkeysS Kumar, L Dare, J A Vasko-Moser, et al.
Bone|May 9, 2002
A potent small molecule, nonpeptide inhibitor of cathepsin K (SB 331750) prevents bone matrix resorption in the ovariectomized ratMichael W Lark, G B Stroup, I E James, et al.
The Journal of Biological Chemistry|June 8, 1999
Identification and cloning of a connective tissue growth factor-like cDNA from human osteoblasts encoding a novel regulator of osteoblast functionsS Kumar, A T Hand, J R Connor, et al.
The Journal of Pharmacology and Experimental Therapeutics|October 19, 1999
Design and characterization of orally active Arg-Gly-Asp peptidomimetic vitronectin receptor antagonist SB 265123 for prevention of bone loss in osteoporosisM W Lark, G B Stroup, S M Hwang, et al.
Bioorganic & Medicinal Chemistry Letters|January 5, 1999
Benzimidazole derivatives as arginine mimetics in 1,4-benzodiazepine nonpeptide vitronectin receptor (alpha v beta 3) antagonistsR M Keenan, W H Miller, M A Lago, et al.
Bioorganic & Medicinal Chemistry Letters|January 5, 1999
Discovery of an imidazopyridine-containing 1,4-benzodiazepine nonpeptide vitronectin receptor (alpha v beta 3) antagonist with efficacy in a restenosis modelR M Keenan, M A Lago, W H Miller, et al.
Journal of Medicinal Chemistry|March 3, 1999
Conformational preferences in a benzodiazepine series of potent nonpeptide fibrinogen receptor antagonistsR M Keenan, J F Callahan, J M Samanen, et al.
Bioorganic & Medicinal Chemistry Letters|July 16, 1999
Orally bioavailable nonpeptide vitronectin receptor antagonists with efficacy in an osteoporosis modelW H Miller, W E Bondinell, R D Cousins, et al.
Journal of Medicinal Chemistry|December 6, 1996
Potent, selective, orally active 3-oxo-1,4-benzodiazepine GPIIb/IIIa integrin antagonistsJ M Samanen, F E Ali, L S Barton, et al.
Journal of Medicinal Chemistry|January 14, 2000
Discovery of orally active nonpeptide vitronectin receptor antagonists based on a 2-benzazepine Gly-Asp mimeticW H Miller, D P Alberts, P K Bhatnagar, et al.
Pageof 13

Showing results (111-120 of 122) with videos related to

Sort By:
Pageof 13
Bone|September 12, 2006
A highly potent inhibitor of cathepsin K (relacatib) reduces biomarkers of bone resorption both in vitro and in an acute model of elevated bone turnover in vivo in monkeysS Kumar, L Dare, J A Vasko-Moser, et al.
Bone|May 9, 2002
A potent small molecule, nonpeptide inhibitor of cathepsin K (SB 331750) prevents bone matrix resorption in the ovariectomized ratMichael W Lark, G B Stroup, I E James, et al.
The Journal of Biological Chemistry|June 8, 1999
Identification and cloning of a connective tissue growth factor-like cDNA from human osteoblasts encoding a novel regulator of osteoblast functionsS Kumar, A T Hand, J R Connor, et al.
The Journal of Pharmacology and Experimental Therapeutics|October 19, 1999
Design and characterization of orally active Arg-Gly-Asp peptidomimetic vitronectin receptor antagonist SB 265123 for prevention of bone loss in osteoporosisM W Lark, G B Stroup, S M Hwang, et al.
Bioorganic & Medicinal Chemistry Letters|January 5, 1999
Benzimidazole derivatives as arginine mimetics in 1,4-benzodiazepine nonpeptide vitronectin receptor (alpha v beta 3) antagonistsR M Keenan, W H Miller, M A Lago, et al.
Bioorganic & Medicinal Chemistry Letters|January 5, 1999
Discovery of an imidazopyridine-containing 1,4-benzodiazepine nonpeptide vitronectin receptor (alpha v beta 3) antagonist with efficacy in a restenosis modelR M Keenan, M A Lago, W H Miller, et al.
Journal of Medicinal Chemistry|March 3, 1999
Conformational preferences in a benzodiazepine series of potent nonpeptide fibrinogen receptor antagonistsR M Keenan, J F Callahan, J M Samanen, et al.
Bioorganic & Medicinal Chemistry Letters|July 16, 1999
Orally bioavailable nonpeptide vitronectin receptor antagonists with efficacy in an osteoporosis modelW H Miller, W E Bondinell, R D Cousins, et al.
Journal of Medicinal Chemistry|December 6, 1996
Potent, selective, orally active 3-oxo-1,4-benzodiazepine GPIIb/IIIa integrin antagonistsJ M Samanen, F E Ali, L S Barton, et al.
Journal of Medicinal Chemistry|January 14, 2000
Discovery of orally active nonpeptide vitronectin receptor antagonists based on a 2-benzazepine Gly-Asp mimeticW H Miller, D P Alberts, P K Bhatnagar, et al.
Pageof 13